Streetbeat News

Analyst Ratings

RCUS

Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on Arcus Biosciences (NYSE:RCUS) but reduced the price target from $38 to $35.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:20 pm

ARQT

Morgan Stanley analyst Nigel Dally has maintained an Overweight rating on Arcutis Biotherapeutics (NASDAQ:ARQT) but reduced the price target from $45 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:18 pm

TALO

Benchmark analyst Subash Chandra has maintained a Buy rating on Talos Energy (NYSE:TALO) but has reduced the price target from $23 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:18 pm

ARVN

Morgan Stanley analyst Terence Flynn has maintained an Equal-Weight rating on Arvinas (NASDAQ:ARVN) but reduced the price target from $32 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:16 pm

APA

Benchmark analyst Subash Chandra has maintained a Buy rating on APA Corporation (NASDAQ:APA) but has reduced the price target from $46 to $43.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:15 pm

BLK

BTCUSD

IYK

LYV

NYCB

On CNBC's 'Halftime Report Final Trades,' Stephen Weiss recommended Bitcoin as it traded above $37,000 following news that BlackRock plans to create an ETF focused on ETH. Jenny Harrington highlighted New York Community Bancorp's 7.5% dividend yield and its better-than-expected Q3 earnings. Josh Brown mentioned Live Nation Entertainment, which has seen consolidation since July and reported strong Q3 revenue. Shannon Saccocia chose iShares US Consumer Staples ETF. NYCB, LYV, and IYK shares all saw gains in the last session.

Portfolio Pulse from Lisa Levin

November 13, 2023 | 2:14 pm

CZR

Morgan Stanley analyst Stephen Grambling has maintained an Equal-Weight rating on Caesars Entertainment (NASDAQ:CZR) but has reduced the price target from $50 to $48.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:14 pm

AKYA

Stephens & Co. analyst Mason Carrico maintains an Overweight rating on Akoya Biosciences (NASDAQ:AKYA) but reduces the price target from $14 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:13 pm

CRSP

Morgan Stanley analyst Terence Flynn has maintained an Underweight rating on CRISPR Therapeutics (NASDAQ:CRSP) and reduced the price target from $43 to $42.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:13 pm

VYX

Charles Nabhan, an analyst at Stephens & Co., has maintained an Overweight rating on NCR Voyix (NYSE:VYX) but reduced the price target from $35 to $19.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:11 pm